Personalis, Inc. - Common Stock (PSNL)

Competitors to Personalis, Inc. - Common Stock (PSNL)

Foundation Medicine, Inc.

Foundation Medicine specializes in genomic profiling of tumors to guide cancer treatment decisions, directly competing with Personalis in the oncology genomic testing space. Foundation Medicine's in-depth analysis and established partnerships with major pharmaceutical companies for targeted therapies and clinical trials create a robust ecosystem that enhances its market position. While Personalis offers personalized genetic insights and has its own strengths in analytical platforms, Foundation's strong ties to drug development and precision medicine initiatives could be seen as giving it the upper hand in influencing treatment protocols.

Guardant Health, Inc. 

Guardant Health is a significant competitor for Personalis predominantly in the realm of liquid biopsy diagnostics for cancer management. Guardant's proprietary Guardant360 test provides a non-invasive method to analyze tumor DNA from a simple blood draw, which can be appealing to both oncologists and patients. This ability to offer real-time genomic insights with minimal discomfort gives Guardant a competitive advantage in patient access and market penetration for cancer diagnostics, although Personalis retains strong offerings in comprehensive genomic profiling.

Illumina, Inc. 

Illumina, as a leader in next-generation sequencing (NGS) technology, competes directly with Personalis by providing comprehensive genomic solutions for clinical and research applications. Illumina's large market share, extensive product portfolio, and established reputation in the sequencing space give it a competitive edge. While Personalis focuses on tailored genomic sequencing and analytics for cancer treatment, Illumina's broad reach and advancements in sequencing technology allow it to serve various genomic research needs, making it a formidable competitor in both precision medicine and oncology diagnostics.

Myriad Genetics, Inc. 

Myriad Genetics is a key player in the hereditary cancer testing and precision medicine space, competing with Personalis by providing tests that guide treatment decisions based on genetic predisposition. Myriad has a strong presence in the market, leveraging its established reputation and wide range of testing services. While Personalis focuses on more comprehensive genomic analyses, Myriad's focus on risk assessment and its history in providing clinical insights give it a competitive foothold in the cancer testing market.

Tempus Labs, Inc.

Tempus Labs competes with Personalis by leveraging technology to offer data-driven insights into cancer care through genomic sequencing and analytics. Tempus specializes in utilizing clinical and molecular data to inform personalized treatment decisions for cancer patients. This advanced data analytics approach and focus on integrating clinical data with genomic data provide Tempus with a unique advantage in the market, making it a significant competitor to Personalis which also seeks to provide personalized insights but with a different focus on stratified genomic profiling.